A Phase 2 interventional study of Decitabine in Myelodysplastic Syndrome, sponsored by Johnson & Johnson Taiwan Ltd. Completed at 6 sites in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-09-09.
Sponsored by Johnson & Johnson Taiwan Ltd (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies testing decitabine in Myelodysplastic Syndromes — 9 open to participants now, 16 under way, 1 of them phase 3. Decitabine · Myelodysplastic Syndromes.
Among the 75 studies testing decitabine in Myelodysplastic Syndromes, this one is the 41st largest by enrollment of the 74 interventional ones that give a count, is one of 6 that started in 2008, is one of 36 in phase 2, and was the 18th registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.
Browse Myelodysplastic Syndromes studies →9 of the 75 studies testing decitabine in Myelodysplastic Syndromes are open now, in 3 countries. Recruiting first, the newest first:
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+ · Healthy volunteers
West Virginia University · Sites in United States
Ages 18+
Beijing 302 Hospital · Sites in China
Ages 18–70
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 60+
Clinical Hub for Interventional Research (CHOIR) · Sites in Australia
Ages 18+
By country, each count listing its studies:
Decitabine: first FDA approval 2006 (DACOGEN), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 49 · Phase 3 6 · Phase 4 3
First in 1995; this study’s year is marked. 6 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is close to the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 43 across the 74 interventional studies. Of the 48 that completed or were terminated, 29 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 75 have an industry lead sponsor. The 10 most frequent:
This study is registered under Johnson & Johnson Taiwan Ltd, one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Taiwan Ltd is the lead sponsor of 23 studies on the registry; none are open to participants now.
21 studies in Myelodysplastic Syndromes by Johnson & Johnson: 1 open now, 1 under way, none of them phase 3. Of 16 finished, 6 (38%) have results posted.
Among the 21 studies in Myelodysplastic Syndromes by Johnson & Johnson, this one is the 11th largest by enrollment of the 17 interventional ones that give a count, is one of 6 that started in 2008, is one of 8 in phase 2, and was the 7th registered.
Johnson & Johnson’s Myelodysplastic Syndromes studies by the year they started, since 1999.
2 of the studies testing decitabine in Myelodysplastic Syndromes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06923488West Virginia UniversityLeflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes | 2027-10 |
| NCT04282187University of WashingtonDecitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | 2027-11-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 75 studies testing decitabine in Myelodysplastic Syndromes, from their registry updates:
Among Johnson & Johnson’s 21 in Myelodysplastic Syndromes:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the response rate of decitabine in previously treated and untreated Taiwanese participants with Myelodysplastic Syndrome (MDS - a disease associated with decreased production of blood cells, blood cells are produced but do not mature normally).
This is an open-label (a medical research study in which participants and researchers are told which treatments the participants are receiving, "unblinded"), multi-center (when more than 1 hospital or medical school team work on a medical research study), single-arm study of decitabine. The study will consist of 5 phases: Pre-treatment phase (before 30 days of first dose), Treatment phase (consist of 8 cycles, each cycle of 28 days), End-of-treatment phase (consist of 30-42 days after the last dose of cycle 8, or at time of discontinuation), Extension phase (1 cycle of 4 weeks) and Post-study phase or follow-up phase (every 2 months until 1 year, lost to follow-up or death). Participants who achieve a complete remission (when a medical problem gets better or goes away at least for a while) will be treated for at least 2 more cycles after first documentation of complete response (CR), after which treatment can be discontinued. Decitabine in a dose of 20 milligram per square meter (mg per m\^2) will be administered intravenously over 1 hour infusion, 1 hour, once daily for 5 consecutive days of a 28 days cycle up to 8 cycles or continued until disease progression or unacceptable toxicity. The primary objective is to evaluate the best response rate (complete response and partial response). Participants' safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Decitabine 20 milligram per square meter (mg per m\^2) will be administered intravenous (into a vein) infusion (a fluid or a medicine delivered into a vein by way of a needle) over 1 hour, once daily for 5 consecutive days of a 28 days cycle up to 8 cycles or continued until disease progression or unacceptable toxicity.
Drug: Decitabine
Decitabine 20 mg per m\^2 will be administered intravenous infusion over 1 hour, once daily for 5 consecutive days of a 28 days cycle up to 8 cycles or continued until disease progression or unacceptable toxicity.
Also known as: Dacogen, 5-aza-2'-deoxycytidine
Percentage of Participants With Response
Percentage of participants with response: complete response (CR) or partial response (PR) according to International Working Group (IWG) 2006 criteria was evaluated. CR in bone marrow is defined as\<=to 5% myeloblasts with normal maturation of all cell lines and persistent dysplasia was noted in peripheral blood hemoglobin \>=11 gram (g) per deciliter (dl), platelets \>=100\*10\^9 liter (l), neutrophils \>=1.0\*10\^9 l, Blasts 0%. Partial response is defined as all CR criteria if abnormal before treatment except: bone marrow blasts decreased by \>=50% over pre-treatment but still \>=5%.
Time frame: Day 1 of Cycle 2, 4, 6, 8; each Cycle of 28 days and End of treatment (30-42 days after Cycle 8 or early withdrawal)
Percentage of Participants With Hematologic Treatment Response
Hematologic treatment response was assessed as per IWG 2006 criteria. This is measured in erythroid(HI-E), platelet(HI-P) and neutrophil(HI-N) lineages. HI-E response(pre-treatment\<11 gram per deciliter \[g/dl\]):hemoglobin increase by\>=1.5 g/dl and relevant reduction in RBC transfusions by 4 RBC transfusions/8week. HI-P response (pre-treatment\<100\*109/l):absolute increase of \>=30\*10\^9/l for participants starting with\>20\*10\^9/l and increase from \<20\*10\^9/l to\>20\*10\^9/l and by at least 100%. HI-N response (pre-treatment\<1.0\*10\^9/l): at least 100% increase and an absolute increase \>0.5\*10\^9/l.
Time frame: Day 1 of Cycle 1, 2, 3, 4, 5, 6, 7 and 8, each Cycle of 28 days and End of treatment (30-42 days after Cycle 8 or early withdrawal)
Percentage of Participants With Cytogenetic Response
Cytogenetic responses was assessed as per IWG 2006 criteria which define complete response as disappearance of the chromosomal abnormality without appearance of new ones and partial response as at least 50 percent reduction of the chromosomal abnormality.
Time frame: Day 1 of Cycle 2, 4, 6, 8; each Cycle of 28 days and End of treatment (30-42 days after Cycle 8 or early withdrawal)
Time to Acute Myeloid Leukemia (AML) Progression or Death
Time to AML is defined as greater than 30 percent of blasts in bone marrow or the time to death was calculated from the date of treatment start until disease progression to AML or until death, which ever occurred first. Participants who were still alive and did not progress to AML were censored at the moment of last visit.
Time frame: Start of treatment until disease progression or death (whichever occur first) or up to 736 days
Overall Survival
Overall survival was defined as the time from the date of treatment start until death (whatever the cause). It was calculated from Kaplan-Meier estimates. Participants still alive were censored at the moment of last visit or contact.
Time frame: Start of treatment until disease progression or death (whichever occur first) or up to 736 days
Percentage of Participants With Transfusion Dependency
Transfusion requirements for both red blood cells as well as platelets were recorded for each participant.
Time frame: 8 weeks before first dose until disease progression or death (whichever occur first) or up to 736 days
Percentage of Participants With Transfusion Independency
Transfusion independent participants were calculated from all the participants who required transfusion in the duration of 8 weeks before first dose until disease progression or death or up to 736 days. Transfusion independence was defined as lack of requirement for transfusions for at least 8 weeks.
Time frame: 8 weeks before first dose and 736 days of treatment
Duration for Hospitalization
Duration of hospitalization was calculated for each participant, using the sum of all hospital days by subtracting the date of discharge from the date of admission.
Time frame: Cycle 1 up to Cycle 8, each cycle of 28 days.
Number of Events Which Led to Hospitalization
The events (reasons) for hospitalizations such as infection, transfusion, acute choleycystitis, allergic transfusion reaction, dyspnoea with right pleural effusion, febrile neutropenia, fever, for decitabine, Myelodysplastic Syndrome (MDS) hematuria, paronychia, pneumonia, heart failure, peri-anal abscess (PAA), pancytopenia,fluctuated neutropenia fever, right dorsal foot cellulitis, Right lower (Rt.Lw) lung pneumonia with impending respiratory (resp) failure, Serious adverse event (SAE)+schedule hospitalization for decitabine, septic shock and not available were reported.
Time frame: Start of treatment until disease progression or death or up to Cycle 8, each cycle of 28 days
Quality of Life Assessment
The quality of life was assessed by the questionnaire QLQ C-30 designed by European Organization for the Research and Treatment of Cancer (EORTC). EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer participants. Most questions used 4-point scale (1=Not at All' to 4=Very Much') and 2 questions: Q29 on overall health and Q30 on overall quality of life uses 7-point scale ranging from 1=Very Poor to 7=Excellent. Higher score indicates better quality of life.
Time frame: Day 1 of Cycle 1 and Cycle 8 (each cycle of 28 days)
| Milestone | Decitabine |
|---|---|
| Started | 37 |
| Completed | 16 |
| Not completed | 21 |
| Withdrew: Objective disease progression | 7 |
| Withdrew: Physician decision | 5 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Death | 6 |
| Withdrew: Adverse event | 2 |
Percentage of participants with response: complete response (CR) or partial response (PR) according to International Working Group (IWG) 2006 criteria was evaluated. CR in bone marrow is defined as\<=to 5% myeloblasts with normal maturation of all cell lines and persistent dysplasia was noted in peripheral blood hemoglobin \>=11 gram (g) per deciliter (dl), platelets \>=100\*10\^9 liter (l), neutrophils \>=1.0\*10\^9 l, Blasts 0%. Partial response is defined as all CR criteria if abnormal before treatment except: bone marrow blasts decreased by \>=50% over pre-treatment but still \>=5%.
| Percentage of Participants | Decitabine |
|---|---|
| Percentage of Participants With Response | 23.5 |
Hematologic treatment response was assessed as per IWG 2006 criteria. This is measured in erythroid(HI-E), platelet(HI-P) and neutrophil(HI-N) lineages. HI-E response(pre-treatment\<11 gram per deciliter \[g/dl\]):hemoglobin increase by\>=1.5 g/dl and relevant reduction in RBC transfusions by 4 RBC transfusions/8week. HI-P response (pre-treatment\<100\*109/l):absolute increase of \>=30\*10\^9/l for participants starting with\>20\*10\^9/l and increase from \<20\*10\^9/l to\>20\*10\^9/l and by at least 100%. HI-N response (pre-treatment\<1.0\*10\^9/l): at least 100% increase and an absolute increase \>0.5\*10\^9/l.
| Percentage of participants | Decitabine |
|---|---|
| Cycle 1: HI-E | 5.9 |
| Cycle 1: HI-P | 8.8 |
| Cycle 1: HI-N | 2.9 |
| Cycle 2: HI-E | 17.2 |
| Cycle 2: HI-P | 27.6 |
| Cycle 2: HI-N | 6.9 |
| Cycle 3: HI-E | 28.6 |
| Cycle 3: HI-P | 39.3 |
| Cycle 3: HI-N | 17.9 |
| Cycle 4: HI-E | 37.0 |
| Cycle 4: HI-P | 33.3 |
| Cycle 4: HI-N | 7.4 |
| Cycle 5: HI-E | 40.9 |
| Cycle 5: HI-P | 40.9 |
| Cycle 5: HI-N | 13.6 |
| Cycle 6: HI-E | 52.4 |
| Cycle 6: HI-P | 61.9 |
| Cycle 6: HI-N | 19.1 |
| Cycle 7: HI-E | 47.1 |
| Cycle 7: HI-P | 52.9 |
| Cycle 7: HI-N | 5.9 |
| Cycle 8: HI-E | 43.8 |
| Cycle 8: HI-P | 56.3 |
| Cycle 8: HI-N | 12.5 |
| End of treatment: HI-E | 27.6 |
| End of treatment: HI-P | 34.5 |
| End of treatment: HI-N | 6.9 |
Cytogenetic responses was assessed as per IWG 2006 criteria which define complete response as disappearance of the chromosomal abnormality without appearance of new ones and partial response as at least 50 percent reduction of the chromosomal abnormality.
| Percentage of participants | Decitabine |
|---|---|
| Cycle 2, Complete Response (n=18) | 22.2 |
| Cycle 2, Partial Response (n=18) | 0.0 |
| Cycle 4, Complete Response (n=20) | 20.0 |
| Cycle 4, Partial Response (n=20) | 25.0 |
| Cycle 6, Complete Response (n=11) | 18.2 |
| Cycle 6, Partial Response (n=11) | 27.3 |
| Cycle 8, Complete Response (n=6) | 0.0 |
| Cycle 8, Partial Response (n=6) | 0.0 |
| End of treatment, Complete Response (n=17) | 11.8 |
| End of treatment, Partial Response (n=17) | 5.9 |
Time to AML is defined as greater than 30 percent of blasts in bone marrow or the time to death was calculated from the date of treatment start until disease progression to AML or until death, which ever occurred first. Participants who were still alive and did not progress to AML were censored at the moment of last visit.
| Months | Decitabine |
|---|---|
| Time to Acute Myeloid Leukemia (AML) Progression or Death | 22.8 (0.3 to 25.4) |
Overall survival was defined as the time from the date of treatment start until death (whatever the cause). It was calculated from Kaplan-Meier estimates. Participants still alive were censored at the moment of last visit or contact.
| Months | Decitabine |
|---|---|
| Overall Survival | 22.8 (0.3 to 25.4) |
Transfusion requirements for both red blood cells as well as platelets were recorded for each participant.
| Percentage of participants | Decitabine |
|---|---|
| Percentage of Participants With Transfusion Dependency | 100 |
Transfusion independent participants were calculated from all the participants who required transfusion in the duration of 8 weeks before first dose until disease progression or death or up to 736 days. Transfusion independence was defined as lack of requirement for transfusions for at least 8 weeks.
| percentage of participants | Decitabine |
|---|---|
| Percentage of Participants With Transfusion Independency | 27 |
Duration of hospitalization was calculated for each participant, using the sum of all hospital days by subtracting the date of discharge from the date of admission.
| Days | Decitabine |
|---|---|
| Cycle 1 (n=37) | 9.0 ± 9.4 |
| Cycle 2 (n=30) | 15.4 ± 16.2 |
| Cycle 3 (n=28) | 13.3 ± 11.5 |
| Cycle 4 (n=28) | 27.1 ± 52.9 |
| Cycle 5 (n=22) | 22.5 ± 38.6 |
| Cycle 6 (n=21) | 7.5 ± 5.0 |
| Cycle 7 (n=17) | 33.3 ± 56.5 |
| Cycle 8 (n=16) | 5.0 ± 0.0 |
The events (reasons) for hospitalizations such as infection, transfusion, acute choleycystitis, allergic transfusion reaction, dyspnoea with right pleural effusion, febrile neutropenia, fever, for decitabine, Myelodysplastic Syndrome (MDS) hematuria, paronychia, pneumonia, heart failure, peri-anal abscess (PAA), pancytopenia,fluctuated neutropenia fever, right dorsal foot cellulitis, Right lower (Rt.Lw) lung pneumonia with impending respiratory (resp) failure, Serious adverse event (SAE)+schedule hospitalization for decitabine, septic shock and not available were reported.
| Events | Decitabine |
|---|---|
| Infection | 10 |
| Transfusion | 4 |
| Acute choleycystitis | 1 |
| Allergic transfusion reaction | 1 |
| Dyspnoea with right pleural effusion | 4 |
| Febrile neutropenia | 16 |
| Fever | 4 |
| For Decitabine | 33 |
| MDS hematuria | 2 |
| Paronychia, pneumonia, heart failure | 1 |
| PAA,pancytopenia,fluctuated neutropenia fever | 1 |
| Right dorsal foot cellulitis | 1 |
| Rt Lw lung pneumonia with impending resp. failure | 1 |
| SAE+Schedule hospitalization for Decitabine | 4 |
| Septic shock | 1 |
| Not available | 36 |
The quality of life was assessed by the questionnaire QLQ C-30 designed by European Organization for the Research and Treatment of Cancer (EORTC). EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer participants. Most questions used 4-point scale (1=Not at All' to 4=Very Much') and 2 questions: Q29 on overall health and Q30 on overall quality of life uses 7-point scale ranging from 1=Very Poor to 7=Excellent. Higher score indicates better quality of life.
| Unit on a scale | Decitabine |
|---|---|
| Baseline, Q29 | 4.4 ± 1.5 |
| Baseline, Q30 | 4.9 ± 1.3 |
| End of treatment, Q29 | 4.3 ± 1.7 |
| End of treatment, Q30 | 4.5 ± 1.8 |
Collected over Baseline up to 30 days after last medication. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Decitabine | — | 28/37 (75.7%) | 37/37 (100%) |
| Event | Decitabine |
|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 19/37 |
| PneumoniaInfections and infestations | 7/37 |
| PyrexiaGeneral disorders | 5/37 |
| Septic shockInfections and infestations | 4/37 |
| AnaemiaBlood and lymphatic system disorders | 3/37 |
| PancytopeniaBlood and lymphatic system disorders | 3/37 |
| Multi-organ failureGeneral disorders | 3/37 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 3/37 |
| NeutropeniaBlood and lymphatic system disorders | 2/37 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/37 |
| Event | Decitabine |
|---|---|
| LeucopeniaBlood and lymphatic system disorders | 28/37 |
| AnaemiaBlood and lymphatic system disorders | 23/37 |
| NeutropeniaBlood and lymphatic system disorders | 22/37 |
| ThrombocytopeniaBlood and lymphatic system disorders | 20/37 |
| NauseaGastrointestinal disorders | 14/37 |
| Decreased appetiteMetabolism and nutrition disorders | 14/37 |
| DizzinessNervous system disorders | 14/37 |
| CoughRespiratory, thoracic and mediastinal disorders | 14/37 |
| PyrexiaGeneral disorders | 13/37 |
| FatigueGeneral disorders | 13/37 |
| Age Continuous(Years) | Decitabine |
|---|---|
| Mean | 68.0 ± 14.1 |
| Sex: Female, Male(Participants) | Decitabine |
|---|---|
| Female | 11 |
| Male | 26 |
The record gives a start of Aug 2008, a primary completion of Sep 2010 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 2 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Decitabine
Johnson & Johnson Taiwan Ltd →